Bladder Cancer VL

Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams

Details
Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...

ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...

Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas

Details
Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...

Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi

Details
In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising amo...

The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak

Details
Eugene Pietzak, MD, Assistant Attending Surgeon of Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City received one of the five 2021 Bladder Cancer Advocacy Network (BCAN) New Discoveries Young Investigator Awards for his work in “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.” There are relatively well-established molecul...

The Management of Primary Carcinoma of The Urethra - Reza Mehrazin

Details
In a presentation, followed by an educational discussion, from Reza Mehrazin, MD, the topic of management of primary urothelial carcinoma is discussed in depth. Dr. Mehrazin began his presentation with epidemiology and risk factors for this aggressive disease. He discussed the risk factor of advanced age (>60 years old) along with other less-known risk factors, such as chronic urethral irritation....

Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova

Details
Svetlana Avulova, MD, Urologic Oncology Fellow at Mayo Clinic received the 2021 BCAN New Discoveries Young Investigator Award for Patient-Centered Research. In this conversation with Ashish Kamat, MD she highlights her project titled “Sexual Function in Women Undergoing Radical Cystectomy”. There is a lack of research on women's quality of life, specifically, on the effect of radical cystectomy on...

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar

Details
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

Details
With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...

Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan

Details
Yair Lotan joins Ashish Kamat in a slide presentation discussion on urine markers for hematuria and bladder cancer. Dr. Lotan overviews a number of recently published papers and new studies in this space. He highlights limitations and challenges with cytology, the current role of markers and where they stand in clinical use, and urinary markers that are available as well as in development for pati...